Pfizer announced Thursday that you have not seen any evidence that circulating COVID-19 variants cause a loss in protection provided by the vaccine they developed with BioNTech, Reuters reported.
“We have not observed changes in neutralizing antibody levels that could predict a significant reduction in protection given by two doses of BNT162B2,” Pfizer stated.
.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
